GO:0036471 cellular response to glyoxal: Stress Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0036471 (cellular response to glyoxal) describes how a cell changes its state or activity in response to glyoxal, a reactive dicarbonyl metabolite.
• Glyoxal and its close relative methylglyoxal modify proteins by glycation, forming advanced glycation end products (AGEs) that alter protein function.
• A central adaptive axis is the KEAP1-NRF2 pathway: methylglyoxal-derived protein modification of KEAP1 activates NRF2-dependent cytoprotective gene expression.
• NRF2 target genes such as AKR7A2 and autophagy-related machinery help cells detoxify glyoxal and clear glycated proteins.
• Glyoxal/methylglyoxal stress is linked to diabetic wound healing, cancer radioimmunotherapy responses, myeloid-derived suppressor cell expansion, and neurodegeneration.
• CRISPR knockout, point-mutation, knock-in, overexpression models and CRISPR library screening are key tools for dissecting glyoxal response genes.
Description
GO:0036471, cellular response to glyoxal, is a Gene Ontology biological process term defined as any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glyoxal stimulus. Glyoxal is a reactive alpha-oxoaldehyde and dicarbonyl compound generated during glycolysis, lipid peroxidation, and food processing, and it is a major precursor of advanced glycation end products (AGEs). Because glyoxal reacts with arginine and lysine residues on proteins, it acts as a metabolic stress signal that cells must sense, detoxify, and adapt to. For researchers, GO:0036471 matters because it sits at the intersection of metabolism, redox biology, proteostasis, and immunity. Methylglyoxal, the closely related dicarbonyl, covalently modifies KEAP1 and thereby activates the KEAP1-NRF2 cytoprotective program, directly integrating glycolysis with stress signaling. In cancer models, methylglyoxal derived from gut microbes can trigger endoplasmic reticulum stress and cGAS-STING activation, boosting radiosensitivity and radioimmunotherapy in rectal cancer. In diabetes, methylglyoxal impairs macrophage function and delays wound repair, an effect that can be ameliorated by carbonyl scavengers such as pyridoxamine. Studying cellular response to glyoxal therefore requires tools that can resolve metabolite-driven protein modification, transcriptional adaptation, and downstream physiological outcomes. This article summarizes the QuickGO definition, the core mechanisms, the key genes, disease links, and the CRISPR-based experimental strategies used to interrogate GO:0036471.
cellular response to glyoxal At A Glance
| GO ID | GO:0036471 |
|---|---|
| GO term | cellular response to glyoxal |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Definition | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a glyoxal stimulus. |
| Major function | Sensing and adapting to glyoxal/dicarbonyl stress, including detoxification and clearance of glycated proteins |
| Key signaling axis | KEAP1-NRF2 cytoprotective signaling activated by dicarbonyl-derived protein modification |
| Representative triggers | Glyoxal and methylglyoxal from glycolysis, gut microbial metabolism, and dietary glycation compounds |
| Disease relevance | Diabetes and impaired wound healing, cancer therapy response, neurodegeneration |
What Is GO:0036471?
In our own words, GO:0036471 (cellular response to glyoxal) is the collection of cellular processes triggered when a cell encounters glyoxal. It covers sensing of the glyoxal stimulus, changes in gene expression and enzyme production, detoxification of the reactive dicarbonyl, repair or removal of glycated macromolecules, and any resulting shifts in cell movement, secretion, or survival. It is a biological_process term, meaning it describes a coordinated cellular program rather than a single molecule or location.
Why Is cellular response to glyoxal Important in Cell Biology?
Cellular response to glyoxal is important because glyoxal and related dicarbonyls are unavoidable byproducts of normal metabolism and of dietary intake, and their accumulation drives protein damage through glycation and AGE formation. Cells must therefore mount adaptive responses, and failure to do so contributes to diabetic complications, impaired tissue repair, and age-related pathology. At the same time, the same stress response can be exploited therapeutically: methylglyoxal-induced endoplasmic reticulum stress and cGAS-STING activation can enhance radiosensitivity and radioimmunotherapy in rectal cancer, and turning off methylglyoxal stress has been proposed as an approach to limit myeloid-derived suppressor cell expansion and metastasis in triple-negative breast cancer. Understanding GO:0036471 thus has both mechanistic and translational value.
• Glyoxal is a major precursor of advanced glycation end products, linking metabolism to protein damage.
• Methylglyoxal modification of KEAP1 activates NRF2, integrating glycolysis with cytoprotective gene expression.
• NRF2-dependent induction of AKR7A2 is part of the adaptive response to methylglyoxal in hepatic cells.
• Methylglyoxal from gut microbes can trigger ER stress and cGAS-STING activation, enhancing rectal cancer radiosensitivity.
• Methylglyoxal impairs macrophage function in diabetic wounds, and carbonyl scavenging can restore tissue repair.
• Glyoxal/methylglyoxal stress is implicated in Alzheimer's disease and anti-AGE defense mechanisms.
• Methylglyoxal stress supports myeloid-derived suppressor cell expansion and metastasis in triple-negative breast cancer.
• NRF2-mediated autophagic degradation of glycated vimentin in skin highlights proteostatic clearance of glycated proteins.
• The pathway is a target for dietary and pharmacological modulation by glycation-compound exposure.
• CRISPR-based models enable causal testing of glyoxal response genes in disease contexts.
What Happens During cellular response to glyoxal?
Sensing the glyoxal stimulus
In simple terms: The cell first has to notice that glyoxal is present and chemically modifying its proteins.
Glyoxal and methylglyoxal are reactive dicarbonyls that covalently modify nucleophilic residues such as arginine and lysine, generating advanced glycation end products. This modification acts as a stress signal: for example, methylglyoxal-derived modification of KEAP1 converts it into a signal that activates NRF2-dependent transcription. Thus the sensing step is largely chemical, driven by metabolite-derived protein modification rather than by a dedicated receptor.
Transcriptional adaptation via NRF2
In simple terms: The cell switches on a protective gene program to cope with the stress.
A central adaptive output of glyoxal/methylglyoxal stress is activation of the KEAP1-NRF2 pathway, which integrates glycolysis with cytoprotective signaling. In HepG2 cells, Nrf2-mediated adaptive response to methylglyoxal involves induction of AKR7A2, an aldo-keto reductase that contributes to detoxification. This transcriptional arm is a hallmark of the cellular response to glyoxal.
Detoxification and clearance of glycated proteins
In simple terms: The cell tries to neutralize the reactive compound and remove proteins that were already damaged.
Beyond transcriptional induction of detoxifying enzymes such as AKR7A2, cells can clear glycated proteins through autophagy. NRF2-mediated autophagic degradation of glycated vimentin in the skin by an elastin-derived peptide demonstrates that selective removal of glycated cytoskeletal proteins is part of the response. This proteostatic arm complements direct enzymatic detoxification.
Stress signaling to ER and innate immune pathways
In simple terms: When the stress is strong, it can activate broader danger and immune signaling.
Methylglyoxal from gut microbes can trigger endoplasmic reticulum stress and cGAS-STING activation, which together boost radiosensitivity and radioimmunotherapy in rectal cancer. This shows that cellular response to glyoxal can intersect with ER stress and innate immune sensing, converting a metabolic stress into an immunologically relevant signal.
Physiological and pathological outcomes
In simple terms: Depending on the cell type, the response can either protect or harm the tissue.
In diabetic wounds, methylglyoxal-induced macrophage dysfunction impairs tissue repair, and pyridoxamine ameliorates this dysfunction to facilitate healing. In triple-negative breast cancer, methylglyoxal stress supports myeloid-derived suppressor cell expansion and metastasis, and turning off this stress is proposed as an alternative therapeutic approach. In the nervous system, anti-AGE defenses are discussed as protective against Alzheimer's disease. The outcome of GO:0036471 therefore depends on cell type and magnitude of the stimulus.
Key Genes Involved in GO:0036471 cellular response to glyoxal
The following genes and proteins are experimentally implicated in cellular response to glyoxal and related dicarbonyl stress, based on the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| KEAP1 | Sensor modified by methylglyoxal-derived glycation, leading to NRF2 activation | Links glycolysis to cytoprotective signaling |
| NFE2L2 (NRF2) | Transcription factor driving cytoprotective and detoxification gene expression | Central adaptive node in glyoxal/methylglyoxal response |
| AKR7A2 | Aldo-keto reductase induced by NRF2; contributes to methylglyoxal detoxification | Nrf2-mediated adaptive response marker in HepG2 cells |
| VIM (vimentin) | Cytoskeletal protein that can become glycated and is cleared by autophagy | NRF2-mediated autophagic degradation of glycated vimentin in skin |
| GLO1 | Glyoxalase enzyme that detoxifies methylglyoxal | Core dicarbonyl detoxification enzyme discussed in glycation literature |
| AGER (RAGE) | Receptor for advanced glycation end products | Mediates AGE signaling in diabetes and neurodegeneration |
| STING1 (TMEM173) | Innate immune adaptor activated downstream of cGAS | Methylglyoxal triggers cGAS-STING activation in rectal cancer |
| CGAS (MB21D1) | Cytosolic DNA sensor upstream of STING | Part of methylglyoxal-induced innate immune activation |
| HSPA5 (BiP/GRP78) | ER stress chaperone | ER stress arm of methylglyoxal response in cancer cells |
| DDIT3 (CHOP) | ER stress-induced transcription factor | Downstream of ER stress during methylglyoxal exposure |
| MAP1LC3B (LC3B) | Autophagosome marker | Autophagic clearance of glycated proteins |
| SQSTM1 (p62) | Selective autophagy receptor | Cargo recognition during autophagic degradation of glycated proteins |
| TXN (thioredoxin) | Redox-regulating protein | Redox balance during dicarbonyl stress |
| GCLC | Glutamate-cysteine ligase catalytic subunit; glutathione synthesis | NRF2 target supporting antioxidant defense |
| GCLM | Glutamate-cysteine ligase modifier subunit | NRF2 target supporting glutathione synthesis |
| NQO1 | NAD(P)H quinone dehydrogenase 1 | Classic NRF2 target used as pathway readout |
| SLC7A11 | Cystine/glutamate antiporter | Supports glutathione synthesis under NRF2 control |
| IL6 | Pro-inflammatory cytokine | Macrophage dysfunction and inflammation in diabetic wounds |
How Is cellular response to glyoxal Regulated?
Cellular response to glyoxal is regulated primarily at the level of the KEAP1-NRF2 axis. Under basal conditions KEAP1 targets NRF2 for degradation; dicarbonyl-derived modification of KEAP1 by methylglyoxal disrupts this repression and allows NRF2 to accumulate and drive cytoprotective transcription. NRF2 then induces genes such as AKR7A2 that participate in detoxification, as well as autophagy-related machinery that clears glycated proteins such as vimentin. The response is further modulated by the availability of glyoxalase enzymes and glutathione, which determine the steady-state level of dicarbonyl stress. In disease contexts, the intensity of this regulation influences outcomes ranging from macrophage function in diabetic wounds to myeloid-derived suppressor cell expansion in breast cancer.
cellular response to glyoxal and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NFE2L2 (NRF2) | Diabetes, cancer therapy response, neurodegeneration | Knockout and overexpression cell models with methylglyoxal challenge |
| AKR7A2 | Methylglyoxal detoxification in liver cells | HepG2 knockout and rescue models |
| VIM (vimentin) | Skin aging and glycated protein clearance | Tagged knock-in for autophagy flux tracking |
| STING1 / CGAS | Rectal cancer radioimmunotherapy | Knockout cancer cell lines plus radiation |
| AGER (RAGE) | Diabetic complications and Alzheimer's disease | Overexpression and point-mutation models |
Diabetes and impaired wound healing
Methylglyoxal-induced macrophage dysfunction contributes to poor tissue repair in diabetic wounds, and the carbonyl scavenger pyridoxamine ameliorates this dysfunction to facilitate healing. This places cellular response to glyoxal at the center of diabetic complication biology, where glycation and AGE accumulation impair cellular function.
Cancer therapy response and metastasis
In rectal cancer, methylglyoxal from gut microbes boosts radiosensitivity and radioimmunotherapy by triggering endoplasmic reticulum stress and cGAS-STING activation. Conversely, in triple-negative breast cancer, methylglyoxal stress supports myeloid-derived suppressor cell expansion and metastasis, so turning off this stress is proposed as an alternative therapeutic approach. The same GO process can therefore be either exploited or inhibited depending on tumor context.
Neurodegeneration
Anti-AGE defense mechanisms have been discussed as protective against Alzheimer's disease, linking glycation stress and its cellular responses to neurodegeneration. This suggests that genes controlling glyoxal detoxification and clearance of glycated proteins may modify neurodegenerative risk.
Skin aging and proteostasis
NRF2-mediated autophagic degradation of glycated vimentin in the skin by an elastin-derived peptide illustrates how cellular response to glyoxal intersects with skin proteostasis and aging-related protein damage. This provides a model for studying selective clearance of glycated cytoskeletal proteins.
From cellular response to glyoxal-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Is NRF2 required for adaptation to glyoxal? | NFE2L2 knockout cell line with methylglyoxal dose-response |
| Does KEAP1 modification drive NRF2 activation? | KEAP1 point-mutation knock-in at dicarbonyl-modified residues |
| Which genes detoxify glyoxal? | CRISPR knockout library screening under glyoxal selection |
| How is glycated vimentin cleared? | VIM tagged knock-in with autophagy reporters |
| Does glyoxal stress enhance immunotherapy? | STING1 knockout tumor cells plus radiation and immune co-culture |
| Can carbonyl scavengers rescue macrophage function? | Primary macrophage overexpression models treated with pyridoxamine |
How to Study the cellular response to glyoxal Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptional changes after glyoxal exposure | Defining NRF2-dependent gene programs |
| Proteomics / glycation site mapping | Covalent modification of proteins by glyoxal | Identifying KEAP1 and vimentin glycation |
| LC3B flux assay | Autophagic degradation of glycated proteins | Skin proteostasis models |
| ER stress reporter assay | Activation of the unfolded protein response | Cancer cells under methylglyoxal stress |
| cGAS-STING reporter assay | Innate immune pathway activation | Radioimmunotherapy studies |
| Macrophage functional assay | Phagocytosis and repair capacity | Diabetic wound models |
| CRISPR knockout library screening | Genes required for survival under glyoxal stress | Pathway discovery |
| NRF2 target qPCR panel | Expression of AKR7A2, NQO1, GCLC, GCLM | Pathway activation readout |
Transcriptomic profiling of the glyoxal response
RNA-seq of cells exposed to glyoxal or methylglyoxal can define the transcriptional program downstream of GO:0036471, including NRF2 target genes such as AKR7A2 and antioxidant genes. Comparing wild-type and NRF2-knockout cells isolates NRF2-dependent versus independent components.
Proteomic detection of glycated proteins
Because glyoxal acts by modifying proteins, mass-spectrometry-based proteomics can map glycation sites on targets such as KEAP1 and vimentin. This connects the chemical stimulus to specific molecular lesions.
Autophagy and proteostasis assays
LC3B flux assays and p62/SQSTM1 imaging can quantify autophagic clearance of glycated proteins, as shown for glycated vimentin in skin models. These assays link the response to proteostatic outcomes.
Functional immune and stress assays
ER stress markers, cGAS-STING reporters, and immune co-culture assays can measure how glyoxal stress alters radiosensitivity and immune activation in cancer models, while macrophage functional assays capture diabetic wound phenotypes.
How CRISPR Can Be Used to Study GO:0036471 cellular response to glyoxal
Knockout
CRISPR knockout of NFE2L2, KEAP1, or AKR7A2 allows causal testing of their roles in cellular response to glyoxal. For example, NRF2 knockout cells can be challenged with methylglyoxal to determine which adaptive genes, such as AKR7A2, depend on NRF2. Knockout of STING1 or CGAS can test whether methylglyoxal-induced innate immune activation is required for radiosensitization.
Point Mutation
Point-mutation knock-in can model specific glycation-sensitive residues in KEAP1 or other sensor proteins, testing whether individual modification sites are necessary and sufficient for pathway activation. This approach distinguishes direct chemical modification events from indirect stress effects.
Knock-in
Tagged knock-in of VIM or MAP1LC3B enables real-time tracking of glycated protein clearance by autophagy, as demonstrated for glycated vimentin in skin models. Knock-in reporters for NRF2 targets provide quantitative readouts of pathway activity.
Overexpression
Overexpression of detoxifying enzymes such as AKR7A2, or of NRF2 itself, can test whether enhancing the response protects cells from glyoxal stress. Conversely, overexpression of AGER/RAGE can model AGE-driven signaling in diabetes and neurodegeneration.
How EDITGENE Supports cellular response to glyoxal Research
Researchers studying cellular response to glyoxal-related genes often need to determine whether a candidate gene is causally involved in sensing, detoxifying, or adapting to dicarbonyl stress, rather than merely correlating with it. Establishing causality requires precise genetic models in relevant cell types, combined with metabolite challenge and functional readouts.
Contact EDITGENE today to design your custom CRISPR model for cellular response to glyoxal research.
Frequently Asked Questions About cellular response to glyoxal
What is GO:0036471 cellular response to glyoxal?
GO:0036471 is a Gene Ontology biological process term describing any change in a cell's state or activity, such as movement, secretion, enzyme production, or gene expression, in response to a glyoxal stimulus.
What is glyoxal and why does it stress cells?
Glyoxal is a reactive dicarbonyl metabolite and a major precursor of advanced glycation end products that modify proteins and trigger cellular stress responses.
What genes are involved in cellular response to glyoxal?
Key genes include KEAP1, NFE2L2 (NRF2), AKR7A2, VIM, STING1, CGAS, and GLO1, based on studies of dicarbonyl stress and glycation.
How does methylglyoxal activate NRF2?
Methylglyoxal-derived protein modification of KEAP1 disrupts NRF2 repression, allowing NRF2 to drive cytoprotective gene expression.
Is cellular response to glyoxal involved in diabetes?
Yes, methylglyoxal-induced macrophage dysfunction impairs diabetic wound healing, and carbonyl scavengers such as pyridoxamine can ameliorate it.
Can glyoxal stress affect cancer therapy?
Yes, methylglyoxal from gut microbes boosts radiosensitivity and radioimmunotherapy in rectal cancer via ER stress and cGAS-STING activation, while in triple-negative breast cancer it supports MDSC expansion and metastasis.
What role does autophagy play in the glyoxal response?
NRF2-mediated autophagy can degrade glycated proteins such as vimentin, contributing to proteostasis during dicarbonyl stress.
How do researchers study cellular response to glyoxal?
Common methods include RNA-seq, glycation-site proteomics, LC3B flux assays, ER stress and cGAS-STING reporters, and CRISPR knockout or library screening.
What CRISPR models are useful for glyoxal response research?
Knockout of NFE2L2, KEAP1, AKR7A2, STING1, or CGAS, point-mutation knock-in of KEAP1, tagged knock-in of VIM, and overexpression of detoxifying enzymes are all informative.
Is glyoxal stress linked to neurodegeneration?
Anti-AGE defense mechanisms have been discussed as protective against Alzheimer's disease, linking glycation stress responses to neurodegeneration.
Conclusion
GO:0036471 cellular response to glyoxal captures a metabolically driven stress program that connects glycolysis, protein glycation, redox signaling, proteostasis, and immunity. The KEAP1-NRF2 axis and its downstream targets such as AKR7A2, together with autophagic clearance of glycated proteins, form the core adaptive machinery. Because the same pathway can protect tissues in diabetes and neurodegeneration yet support tumor phenotypes in some cancers, context-specific genetic models are essential. CRISPR-based knockout, point-mutation, knock-in, overexpression, and library screening approaches provide the causal resolution needed to move from correlation to mechanism in glyoxal response research. Combining these models with transcriptomic, proteomic, and functional assays will continue to clarify how cells sense and survive dicarbonyl stress.
References
- 1. Hellwig M et al.. 2024. Dietary glycation compounds - implications for human health.. Crit Rev Toxicol 54(8):485-617 PMID: 39150724
- 2. Bollong MJ et al.. 2018. A metabolite-derived protein modification integrates glycolysis with KEAP1-NRF2 signalling.. Nature 562(7728):600-604 PMID: 30323285
- 3. Zhou H et al.. 2023. Methylglyoxal from gut microbes boosts radiosensitivity and radioimmunotherapy in rectal cancer by triggering endoplasmic reticulum stress and cGAS-STING activation.. J Immunother Cancer 11(11) PMID: 38035726
- 4. Jiang M et al.. 2022. Pyridoxamine ameliorates methylglyoxal-induced macrophage dysfunction to facilitate tissue repair in diabetic wounds.. Int Wound J 19(1):52-63 PMID: 33792156
- 5. Li D et al.. 2015. Nrf2-mediated adaptive response to methyl glyoxal in HepG2 cells involves the induction of AKR7A2.. Chem Biol Interact 234:366-71 PMID: 25451587
- 6. Münch G et al.. 2003. Anti-AGEing defences against Alzheimer's disease.. Biochem Soc Trans 31(Pt 6):1397-9 PMID: 14641072
- 7. Mohring V et al.. 2026. Turning off methylglyoxal stress: an alternative approach to inhibit MDSC expansion and metastasis in triple-negative breast cancer.. J Immunother Cancer 14(8) PMID: 42595355
- 8. Ritter D et al.. 2025. NRF2-mediated autophagic degradation of glycated vimentin in the skin by an elastin-derived peptide.. Am J Transl Res 17(11):8577-8588 PMID: 41415096
